Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul-Aug;28(4):251-9.
doi: 10.5144/0256-4947.2008.251.

Improved outcome for children with acute lymphoblastic leukemia after risk-adjusted intensive therapy: a single-institution experience

Abdallah Al-Nasser  1 , Hassan El-Solh, Edward De Vol, Ibrahim El-Hassan, Ali Alzahrani, Reem Al-Sudairy, Mohammed Al-Mahr, Abdulrahman Al-Musa, Abdulla Al-Jefri, Mahasen Saleh, Samira Rifai, Asim Belgaumi, Layla Osman, Khairy Ashraf, Mohammed Salim, Ameurfina Silo, George Roberts
Affiliations

Improved outcome for children with acute lymphoblastic leukemia after risk-adjusted intensive therapy: a single-institution experience

Abdallah Al-Nasser et al. Ann Saudi Med. 2008 Jul-Aug.

Abstract

Background and objective: Because of the need for more comprehensive information on the least toxic and most effective forms of therapy for children with acute lymphoblastic leukemia (ALL), we reviewed our experience in the treatment of children with ALL at King Faisal Specialist Hospital and Research Centre (KFSH&RC) and King Fahad National Center for Children's Cancer and Research (KFNCCC&R) over a period of 18 years with a focus on patient characteristics and outcome.

Methods: During the period of 1981 to 1998, records of children with ALL were retrospectively reviewed with respect to clinical presentation, laboratory findings, risk factors, stratification, therapy and outcome. The protocols used in treatment included 4 local protocols (KFSH 81, 84, 87 and 90), and subsequently, Children's Cancer Group (CCG) protocols, and these were grouped as Era 1 (1981-1992) and Era 2 (1993-1998).

Results: Of 509 children with ALL treated during this period, 316 were treated using local protocols and 193 using CCG protocols. Drugs used in Era 1 included a 4-drug induction using etoposid (VP-16) instead of L-asparaginase. Consolidation was based on high dose methotrexate (MTX) 1 g/m(2) and maintenance was based on oral mercaptopurine (6-MP) and MTX with periodic pulses using intravenous teniposide (VM-26), Ara-C, L-asparaginase, adriamycin, prednisone, VP-16 and cyclophosphamide. International protocols were introduced in Era 2, which was also marked by intensification of early treatment, a wider selection of cytoreductive agents, and the alternating use of non-cross-resistant pairs of drugs during the post-remission period. The end-of-induction remission rate improved from 90% in Era 1 to 95% in Era 2, which was of borderline statistical significance (P=.049). The 5-year event-free survival (EFS) improved from 30.6% in Era 1 to 64.2% in Era 2 (P<.001). Improvement in outcome was achieved without any significant increase in morbidity or mortality, due to improvement in both systemic therapy and supportive care. The most important independent prognostic factors were intensity of therapy, poor risk category assignment and CNS disease at diagnosis.

Conclusion: Outcome in children with ALL has improved because of intensification of treatment protocols and better supportive care.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Event-free survival in Era 1 and Era 2.
Figure 2
Figure 2
Event-free survival in Era 1 by protocol.
Figure 3
Figure 3
Event-free survival in Era 2 by protocol.
Figure 4
Figure 4
Event-free survival with CCG 1882 protocol per arm.
Figure 5
Figure 5
Treatment-related mortality in Era 1 and Era 2.
Figure 6
Figure 6
Event-free survival in Era 1 according to CNS status.
Figure 7
Figure 7
Event-free survival in Era 2 according to CNS status.
Figure 8
Figure 8
Event-free survival according to DNA index status.
See this image and copyright information in PMC

References

    1. Pui CH, Evans W. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78. - PubMed
    1. Pui CH, Evans W. Acute lymphoblastic leukemic. N Engl J Med. 1998;339:605–15. - PubMed
    1. Ochs J, Mulhern R, Fairclough D, et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: A prospective study. J Clin Oncol. 1991;9:145–51. - PubMed
    1. Lipshultz S, Colan S, Gelber R, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–15. - PubMed
    1. Pui CH, Ribeiro R, Hancock M, et al. Acute myeloid leukemia in children treated with epipodophylotoxins for acute lymphoblastic leukemia. N Eng J Med. 1991;325:1682–7. - PubMed

LinkOut - more resources